1-4 of 4
Ekaterine Asatiani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Free
Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Jason R. Gotlib, MDMS, Adam J. Mead, MD PhD, Andreas Hochhaus, MD, Jean-Jacques Kiladjian, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Ekaterine Asatiani, MD, Christine Lihou, BS, Huiling Zhen, MD PhD, Andreas Reiter, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 690.
https://doi.org/10.1182/blood-2018-99-110388
Published: 2018
Journal Articles

A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies

Free
Amer M. Zeidan, MD, Rachel J. Cook, MD, Rodolfo Bordoni, MD, Ekaterine Asatiani, MD, Gongfu Zhou, Théa Faivre, Michael Byrne, MD, Michael R. Savona, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 640.
https://doi.org/10.1182/blood.V130.Suppl_1.640.640
Published: 2017
Journal Articles

Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run-In Part of a Phase II Trial of Orally Available MEK-Inhibitor MSC1936369 in Patients (Pts) with Advanced Hematological Malignancies (HM)

Free
Farhad Ravandi, MD, Arnaud Pigneux, MD, PhD, Daniel J. DeAngelo, MD, PhD, Hervé Dombret, MD, Jacques Delaunay, MD, Xavier Thomas, MD, PhD, Tapan Kadia, Christian Luepfert, PhD, Ekaterine Asatiani, MD, Margarita Donica, MSc, Hagop M. Kantarjian, B. Douglas Smith, MD
Journal: Blood
Blood (2011) 118 (21): 1554.
https://doi.org/10.1182/blood.V118.21.1554.1554
Published: 2011
Journal Articles

Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run In Part of a Phase II Trial of the Orally Available MEK-Inhibitor MSC1936369 In Patients with Advanced Hematological Malignancies

Free
Farhad Ravandi, MD, Arnaud Pigneux, MD, PhD, Douglas Smith, MD, Hervé Dombret, Xavier Thomas, MD, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, Daniel J DeAngelo, MD, PhD, Keith W Pratz, MD, Ekaterine Asatiani, MD, Athos Gianella-Borradori, MD, Blandine Longerey, Jean-Luc Harousseau
Journal: Blood
Blood (2010) 116 (21): 3296.
https://doi.org/10.1182/blood.V116.21.3296.3296
Published: 2010